111 related articles for article (PubMed ID: 8352699)
1. Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis.
Li PK; Mak TW; Chiu K; Mak GY; Leung CB; Lui SF; Lam CW; Lai KN
Aust N Z J Med; 1993 Jun; 23(3):252-7. PubMed ID: 8352699
[TBL] [Abstract][Full Text] [Related]
2. Lovastatin treatment of dyslipoproteinemia in patients on continuous ambulatory peritoneal dialysis.
Li PK; Mak TW; Lam CW; Lai KN
Perit Dial Int; 1993; 13 Suppl 2():S428-30. PubMed ID: 8399631
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the short term efficacy and tolerability of lovastatin and simvastatin in the management of primary hypercholesterolemia.
Frohlich J; Brun LD; Blank D; Campeau L; Crockford P; Curnew G; Dafoe W; Davignon J; Dufour R; Emery G
Can J Cardiol; 1993 Jun; 9(5):405-12. PubMed ID: 8348392
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
[TBL] [Abstract][Full Text] [Related]
7. Effect of lovastatin on serum lipids in patients with nonfamilial primary hypercholesterolemia.
Itskovitz HD; Flamenbaum W; De Gaetano C; Pritchard KA; Stemerman MB
Clin Ther; 1989; 11(6):862-72. PubMed ID: 2611825
[TBL] [Abstract][Full Text] [Related]
8. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment.
Korhonen T; Hannuksela ML; Seppänen S; Kervinen K; Kesäniemi YA; Savolainen MJ
Eur J Clin Pharmacol; 1999 Feb; 54(12):903-10. PubMed ID: 10192749
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
[TBL] [Abstract][Full Text] [Related]
10. Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.
Wanner C; Lubrich-Birkner I; Summ O; Wieland H; Schollmeyer P
Nephron; 1992; 62(1):40-6. PubMed ID: 1436290
[TBL] [Abstract][Full Text] [Related]
11. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Alaupovic P; Heinonen T; Shurzinske L; Black DM
Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
[TBL] [Abstract][Full Text] [Related]
12. [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
Forti N; Ramires JA
Arq Bras Cardiol; 1991 Sep; 57(3):253-61. PubMed ID: 1824203
[TBL] [Abstract][Full Text] [Related]
13. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin.
Arca M; Vega GL; Grundy SM
JAMA; 1994 Feb; 271(6):453-9. PubMed ID: 8295321
[TBL] [Abstract][Full Text] [Related]
14. Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis.
Marangoni R; Civardi F; Masi F; Cimino R; Maltagliati L; Romei Longhena G
Perit Dial Int; 1993; 13 Suppl 2():S431-3. PubMed ID: 8399632
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin in the treatment of hypercholesterolemia in CAPD.
Krane NK; Stock G; Caballero M; Starks E
Adv Perit Dial; 1992; 8():362-4. PubMed ID: 1361823
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
[TBL] [Abstract][Full Text] [Related]
17. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering effects of lovastatin in CAPD patients.
Jacobs RH; Lal SM; Nolph KD
Adv Perit Dial; 1993; 9():288-90. PubMed ID: 8105945
[TBL] [Abstract][Full Text] [Related]
19. Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients.
Hörkkö S; Huttunen K; Läärä E; Kervinen K; Kesäniemi YA
Ann Med; 1994 Aug; 26(4):271-82. PubMed ID: 7946245
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trial of lovastatin versus gemfibrozil in the treatment of primary hypercholesterolemia].
Catalán M; López de Ocáriz A; Alvarez MP; Ariño M; Azanza JR; Honorato J
Rev Med Univ Navarra; 1992; 37(3):127-33. PubMed ID: 1480917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
